IPHA
Innate PharmaNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$135.11M
P/E Ratio
—
EPS
$-0.64
Beta
0.74
52W High
$2.63
52W Low
$1.17
50-Day MA
$1.48
200-Day MA
$1.82
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Innate Pharma
Innate Pharma SA, a biotechnology company, discovers, develops and markets therapeutic antibodies for the treatment of oncological indications in France and internationally. The company is headquartered in Marseille, France.
Fundamentals
| Revenue (TTM) | $9.01M |
| Gross Profit (TTM) | $-34.62M |
| EBITDA | $-53.31M |
| Operating Margin | -690.00% |
| Return on Equity | -271.40% |
| Return on Assets | -38.90% |
| Revenue/Share (TTM) | $0.10 |
| Book Value | $-0.27 |
| Price-to-Book | 20.10 |
| Price-to-Sales (TTM) | 15.00 |
| EV/Revenue | 36.19 |
| EV/EBITDA | -6.94 |
| Quarterly Earnings Growth (YoY) | -74.70% |
| Quarterly Revenue Growth (YoY) | -46.70% |
| Shares Outstanding | $93.83M |
| Float | $65.91M |
| % Insiders | 1.67% |
| % Institutions | 0.29% |
Historical Volatility
HV 10-Day
60.90%
HV 20-Day
73.29%
HV 30-Day
86.65%
HV 60-Day
69.70%
HV Rank
86.1%
Volatility is currently contracting
Analyst Ratings
Consensus ($6.00 target)
3
Buy1
HoldData last updated: 5/1/2026